Energy News / Shareholders Foundation, Inc.

NASDAQ:HALO Investor Alert: Investigation over Possible Securities Laws Violations by Halozyme Therapeutics, Inc.

Via: ReleaseWire

Updated 11:45 AM CST, Wed, December 12,2018

An investigation for investors in Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares over potential securities laws violations by Halozyme Therapeutics, Inc. was announced.

San Diego, CA -- (SBWIRE) -- 12/12/2018 -- An investigation was announced over potential securities laws violations by Halozyme Therapeutics, Inc. and certain of its directors and officers in connection with certain financial statements.

Investors who purchased shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Halozyme Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

San Diego, CA based Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies.

O January 16, 2018, an abstract detailing a Phase IB/II randomized study of Halozyme's drug PEGPH20 as a treatment for pancreatic cancer in combination with the cancer drug mFFOX was published in connection with a scheduled presentation at the 2018 Gastrointestinal Cancers Symposium. The abstract's authors concluded that the "addition of PEGPH20 to mFFOX is not recommended for further study and appears to be detrimental" after noting that patients who used the combination experienced higher levels of diarrhea, fatigue, nausea, vomiting, and more than those who used mFFOX as a monotherapy.

On November 26, 2018, Halozyme issued a press release announcing "that prior to data analysis, the [U.S. Food and Drug Administration] has agreed to Halozyme's request to change the primary endpoint of the HALO-301 study to the single primary endpoint of overall survival (OS). As a result, the previously planned interim analysis will not be conducted."

On December 3, 2018, NASDAQ:HALO shares closed at $16.58 per share.

Those who purchased shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

For more information on this press release visit:
http://www.sbwire.com/press-releases/nasdaqhalo-investor-alert-investigation-over-possible-securities-laws-violations-by-halozyme-therapeutics-inc-1103098.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com